Phenothiazine-based chalcones as potential dual-target inhibitors toward cholinesterases (AChE, BuChE) and monoamine oxidases (MAO-A, MAO-B)
Özet
Chalcones targeting neurodegenerative diseases have been known as attractive structures in drug design and discovery. In this study, phenothiazine-based chalcones as ChEs and MAOs inhibitors were designed and synthesized via base-catalyzed Claisen-Schmidt condensation, and chemical structures of the compounds were elucidated by NMRs and HRMS. Compounds 3 and 9 showed promising inhibition potency against AChE enzyme with IC50 values of 0.221 μM and 0.053 μM while compound 9 displayed remarkable inhibition potency toward MAO-B enzyme with IC50 value of 0.048 μM. Compound 9, as a dual-target inhibitor, selectively inhibited AChE and MAO-B enzymes. This promising behavior is an advantage for the compound since MAO-B and AChE inhibition have a role in Alzheimer's disease. Fused tricyclic ring systems such as phenothiazine incorporated with chalcone moiety being multitargeting ligands may help scientists for the rational design of novel lead compounds targeting neurodegenerative illnesses. © 2020 Wiley Periodicals LLC.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Yamali, Cem | |
| dc.contributor.author | Engin, Feyza Sena | |
| dc.contributor.author | Bilginer, Sinan | |
| dc.contributor.author | Tugrak, Mehtap | |
| dc.contributor.author | Ozmen Ozgun, Dilan | |
| dc.contributor.author | Ozli, Gulsen | |
| dc.contributor.author | Levent, Serkan | |
| dc.contributor.author | Saglik, Begum Nurpelin | |
| dc.contributor.author | Ozkay, Yusuf | |
| dc.contributor.author | Gul, Halise Inci | |
| dc.date.accessioned | 2026-10-18T20:27:59.842018522Z | |
| dc.date.available | 2026-10-18T20:27:59.842018522Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Chalcones targeting neurodegenerative diseases have been known as attractive structures in drug design and discovery. In this study, phenothiazine-based chalcones as ChEs and MAOs inhibitors were designed and synthesized via base-catalyzed Claisen-Schmidt condensation, and chemical structures of the compounds were elucidated by NMRs and HRMS. Compounds 3 and 9 showed promising inhibition potency against AChE enzyme with IC50 values of 0.221 μM and 0.053 μM while compound 9 displayed remarkable inhibition potency toward MAO-B enzyme with IC50 value of 0.048 μM. Compound 9, as a dual-target inhibitor, selectively inhibited AChE and MAO-B enzymes. This promising behavior is an advantage for the compound since MAO-B and AChE inhibition have a role in Alzheimer's disease. Fused tricyclic ring systems such as phenothiazine incorporated with chalcone moiety being multitargeting ligands may help scientists for the rational design of novel lead compounds targeting neurodegenerative illnesses. © 2020 Wiley Periodicals LLC. | |
| dc.identifier.doi | 10.1002/jhet.4156 | |
| dc.identifier.eissn | 1943-5193 | |
| dc.identifier.endpage | 171 | |
| dc.identifier.issn | 0022-152X | |
| dc.identifier.issue | 1 | |
| dc.identifier.scopus | 2-s2.0-85092590337 | |
| dc.identifier.startpage | 161 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/13155 | |
| dc.identifier.volume | 58 | |
| dc.identifier.wos | WOS:000577946000001 | |
| dc.language.iso | en | |
| dc.publisher | HeteroCorporation | |
| dc.relation.ispartof | Journal of Heterocyclic Chemistry | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | 1 (10h phenothiazin 2 yl) 3 aryl 2 propen 1 one derivative | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (2 fluorophenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (2,4 dichlorophenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (3 bromophenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (3 fluorophenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (3 nitrophenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (3,4 dichlorophenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (3,4 methylenedioxyphenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (4 benzyloxyphenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (4 chlorophenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (4 fluorophenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (4 methoxyphenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (4 methylphenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (4 nitrophenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (4 trifluoromethylphenyl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 (thiophene 2 yl)prop 2 en 1 one | |
| dc.subject | 1 (10h phenothiazine 2 yl) 3 phenyl prop 2 en 1 one | |
| dc.subject | acetylcholinesterase | |
| dc.subject | amine oxidase (flavin containing) isoenzyme A | |
| dc.subject | amine oxidase (flavin containing) isoenzyme B | |
| dc.subject | chalcone derivative | |
| dc.subject | cholinesterase | |
| dc.subject | clorgyline | |
| dc.subject | donepezil | |
| dc.subject | phenothiazine derivative | |
| dc.subject | selegiline | |
| dc.subject | tacrine | |
| dc.subject | unclassified drug | |
| dc.subject | Alzheimer disease | |
| dc.subject | Article | |
| dc.title | Phenothiazine-based chalcones as potential dual-target inhibitors toward cholinesterases (AChE, BuChE) and monoamine oxidases (MAO-A, MAO-B) | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 29 | |
| rdl.citation.wos | 29 | |
| rdl.oa.status | green | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) | |
| rdl.wos.index | Index Chemicus (IC) |
